INCY
Price
$62.53
Change
+$0.50 (+0.81%)
Updated
May 2 closing price
Capitalization
12.1B
92 days until earnings call
XENE
Price
$38.28
Change
+$0.19 (+0.50%)
Updated
May 2 closing price
Capitalization
2.93B
8 days until earnings call
Ad is loading...

INCY vs XENE

Header iconINCY vs XENE Comparison
Open Charts INCY vs XENEBanner chart's image
Incyte
Price$62.53
Change+$0.50 (+0.81%)
Volume$1.53M
Capitalization12.1B
Xenon Pharmaceuticals
Price$38.28
Change+$0.19 (+0.50%)
Volume$1.06M
Capitalization2.93B
INCY vs XENE Comparison Chart
Loading...
INCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INCY vs. XENE commentary
May 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCY is a Hold and XENE is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
May 05, 2025
Stock price -- (INCY: $62.53 vs. XENE: $38.28)
Brand notoriety: INCY: Notable vs. XENE: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INCY: 72% vs. XENE: 145%
Market capitalization -- INCY: $12.1B vs. XENE: $2.93B
INCY [@Biotechnology] is valued at $12.1B. XENE’s [@Biotechnology] market capitalization is $2.93B. The market cap for tickers in the [@Biotechnology] industry ranges from $306.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INCY’s FA Score shows that 1 FA rating(s) are green whileXENE’s FA Score has 2 green FA rating(s).

  • INCY’s FA Score: 1 green, 4 red.
  • XENE’s FA Score: 2 green, 3 red.
According to our system of comparison, XENE is a better buy in the long-term than INCY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INCY’s TA Score shows that 4 TA indicator(s) are bullish while XENE’s TA Score has 7 bullish TA indicator(s).

  • INCY’s TA Score: 4 bullish, 5 bearish.
  • XENE’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, XENE is a better buy in the short-term than INCY.

Price Growth

INCY (@Biotechnology) experienced а +5.70% price change this week, while XENE (@Biotechnology) price change was +1.75% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.30%. For the same industry, the average monthly price growth was +8.07%, and the average quarterly price growth was -4.75%.

Reported Earning Dates

INCY is expected to report earnings on Aug 05, 2025.

XENE is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+4.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INCY($12.1B) has a higher market cap than XENE($2.93B). XENE YTD gains are higher at: -2.347 vs. INCY (-9.469). INCY has higher annual earnings (EBITDA): 408M vs. XENE (-276.74M). INCY has more cash in the bank: 2.16B vs. XENE (627M). XENE has less debt than INCY: XENE (9.02M) vs INCY (43.5M). INCY has higher revenues than XENE: INCY (4.24B) vs XENE (0).
INCYXENEINCY / XENE
Capitalization12.1B2.93B413%
EBITDA408M-276.74M-147%
Gain YTD-9.469-2.347403%
P/E Ratio312.65N/A-
Revenue4.24B0-
Total Cash2.16B627M344%
Total Debt43.5M9.02M483%
FUNDAMENTALS RATINGS
INCY vs XENE: Fundamental Ratings
INCY
XENE
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
98
Overvalued
PROFIT vs RISK RATING
1..100
10033
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5847
P/E GROWTH RATING
1..100
15
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INCY's Valuation (92) in the Biotechnology industry is in the same range as XENE (98). This means that INCY’s stock grew similarly to XENE’s over the last 12 months.

XENE's Profit vs Risk Rating (33) in the Biotechnology industry is significantly better than the same rating for INCY (100). This means that XENE’s stock grew significantly faster than INCY’s over the last 12 months.

XENE's SMR Rating (100) in the Biotechnology industry is in the same range as INCY (100). This means that XENE’s stock grew similarly to INCY’s over the last 12 months.

XENE's Price Growth Rating (47) in the Biotechnology industry is in the same range as INCY (58). This means that XENE’s stock grew similarly to INCY’s over the last 12 months.

INCY's P/E Growth Rating (1) in the Biotechnology industry is in the same range as XENE (5). This means that INCY’s stock grew similarly to XENE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INCYXENE
RSI
ODDS (%)
Bullish Trend 4 days ago
57%
Bullish Trend 4 days ago
80%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
71%
Bearish Trend 4 days ago
88%
Momentum
ODDS (%)
Bullish Trend 4 days ago
59%
Bullish Trend 4 days ago
76%
MACD
ODDS (%)
Bullish Trend 4 days ago
67%
Bullish Trend 4 days ago
71%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
63%
Bullish Trend 4 days ago
75%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
58%
Bullish Trend 4 days ago
75%
Advances
ODDS (%)
Bullish Trend 6 days ago
60%
Bullish Trend 7 days ago
73%
Declines
ODDS (%)
Bearish Trend 20 days ago
63%
Bearish Trend 5 days ago
74%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
62%
Bullish Trend 4 days ago
76%
Aroon
ODDS (%)
Bearish Trend 4 days ago
60%
Bearish Trend 4 days ago
83%
View a ticker or compare two or three
Ad is loading...
INCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ZIG33.770.64
+1.95%
The Acquirers ETF
IWF376.935.31
+1.43%
iShares Russell 1000 Growth ETF
XSEP38.950.26
+0.67%
FT Vest U.S. Eq Enh & ModBufETF-Sep
FXY63.560.27
+0.43%
Invesco CurrencyShares® Japanese Yen
UNIY48.56N/A
N/A
WisdomTree Voya Yld Enh USD Unvsl Bd Fd

INCY and

Correlation & Price change

A.I.dvisor indicates that over the last year, INCY has been loosely correlated with REGN. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if INCY jumps, then REGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INCY
1D Price
Change %
INCY100%
+0.81%
REGN - INCY
39%
Loosely correlated
+2.65%
AXON - INCY
39%
Loosely correlated
+1.14%
TECH - INCY
37%
Loosely correlated
+1.73%
KYMR - INCY
34%
Loosely correlated
+2.11%
XENE - INCY
34%
Loosely correlated
+0.50%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with IDYA. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
+0.50%
IDYA - XENE
53%
Loosely correlated
+2.25%
KYMR - XENE
53%
Loosely correlated
+2.11%
RCKT - XENE
51%
Loosely correlated
+1.91%
CRNX - XENE
51%
Loosely correlated
+1.11%
ATXS - XENE
50%
Loosely correlated
+3.88%
More